Zealand Pharma to Report 2025 Financial Results Amid Late-Stage Pipeline Push
Event summary
- Zealand Pharma will host a conference call on February 19, 2026, at 2:00 pm CET to present full-year 2025 financial results.
- Key participants include CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall.
- The company has three drug candidates in late-stage development, with two products already marketed.
- Zealand Pharma focuses on obesity and metabolic health, leveraging AI/ML and peptide R&D expertise.
The big picture
Zealand Pharma's upcoming earnings call comes as the biotech sector faces increasing pressure to deliver on late-stage pipeline candidates. The company's focus on obesity and metabolic health aligns with a growing global demand for innovative treatments in these areas. Investors will be watching closely to see if Zealand Pharma can maintain its momentum in a competitive market.
What we're watching
- Pipeline Progress
- How Zealand Pharma's three late-stage candidates will impact its 2026 outlook.
- Financial Health
- Whether the company's 2025 results reflect sustainable revenue growth from marketed products.
- Strategic Partnerships
- The pace at which Zealand Pharma expands collaborations to advance its obesity and metabolic health portfolio.
Related topics